Ecliptasaponin A

Synonyms: 旱莲苷A
Ecliptasaponin A 是一种口服有效的五环三萜皂苷,通过激活 ASK1/JNK 通路诱导肺癌细胞凋亡 (apoptosis) 和自噬 (autophagy) 发挥抗肿瘤活性,通过抑制 HMGB1/TLR4/NF-κB 通路、COX-2 和 MMP9 表达发挥抗炎/抗纤维化作用并保护心血管系统,通过增强 SOD 活性、降低 MDA 水平减轻氧化应激损伤,通过抑制 MMP13 表达、调节炎症因子发挥软骨保护作用,并通过上调 ESR1 受体表达改善卵巢功能、调节性激素。
产品编号: MS-H25906 纯度: 99.81% CAS No.: 78285-90-2 分子式: C36H58O9 分子量: 634.84
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
20mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Ecliptasaponin A 是一种口服有效的五环三萜皂苷,通过激活 ASK1/JNK 通路诱导肺癌细胞凋亡 (apoptosis) 和自噬 (autophagy) 发挥抗肿瘤活性,通过抑制 HMGB1/TLR4/NF-κB 通路、COX-2 和 MMP9 表达发挥抗炎/抗纤维化作用并保护心血管系统,通过增强 SOD 活性、降低 MDA 水平减轻氧化应激损伤,通过抑制 MMP13 表达、调节炎症因子发挥软骨保护作用,并通过上调 ESR1 受体表达改善卵巢功能、调节性激素。

生物实验数据

生物活性 Ecliptasaponin A is an orally active pentacyclic triterpenoid saponin that exerts antitumor activity by inducing apoptosis and autophagy in lung cancer cells via activation of the ASK1/JNK pathway, exerts anti-inflammatory/anti-fibrotic effects and protects the cardiovascular system by inhibiting the HMGB1/TLR4/NF-κB pathway and COX-2 and MMP9 expression, alleviates oxidative stress injury by enhancing SOD activity and reducing MDA levels, exerts chondroprotective effects by inhibiting MMP13 expression and modulating inflammatory factors, and improves ovarian function and regulates sex hormones by upregulating ESR1 receptor expression.
IC50 & Target

MMP-9

 

MMP-13

 

MMP-2

 

NF-κB

 

COX-2

 

TLR4

 

体外研究
(In Vitro)

Ecliptasaponin A (5-20 μM) 可抑制 HMGB1/TLR4/NF-κB 通路,对氧糖剥夺 (OGD) 的 H9C2 细胞发挥保护作用。
Ecliptasaponin A (0-120 μM, 24-48 h) 对 H460 和 H1975 细胞的活力及集落形成能力表现出剂量和时间依赖性抑制。
Ecliptasaponin A (0-30 μM, 24 h) 通过激活 ASK1/JNK 通路和自噬,在 H460 和 H1975 细胞中诱导凋亡。
Ecliptasaponin A (5-30 μM, 48 h) 抑制转化生长因子-β1 (TGFβ1) 诱导的人肾-2 (HK-2) 细胞中 ECM 和 MMP13 的表达。
Ecliptasaponin A (0-25 μM) 靶向 ESR1 蛋白,在环磷酰胺 (MS-C45849) 诱导的 AW-CCH252 细胞损伤中提高细胞活力并减少凋亡。
Ecliptasaponin A (10-50 ng/mL, 25 h) 在 IL-1β 刺激的 SW1353 细胞中,所有骨关节炎相关分子的表达均降低。

Cell Viability Assay

Cell Line: H460 and H1975 cells
Concentration: 0, 20, 40, 60, 80, 100 and 120 μM
Incubation Time: 24 and 48 h
Result: Significantly induced cell death in both dose-dependent and time-dependent ways.

Apoptosis Analysis

Cell Line: H460 and H1975 cells
Concentration: 0, 10, 20 and 30 μM
Incubation Time: 24 h
Result: Dose-dependently increased the proportion of apoptotic cells, with early apoptosis (Annexin V+/PI-) being the predominant type.
Displayed typical apoptotic features: nuclear shrinkage, chromatin condensation, nuclear fragmentation, and the formation of apoptotic bodies.

Western Blot Analysis

Cell Line: H460 and H1975 cells
Concentration: 0, 10, 20 and 30 μM
Incubation Time: 24 h
Result: Increased the Caspase-3/8/9 cleavage products and PARP cleavage.
Increased the LC3-II/I ratio, upregulated Beclin-1 expression, and accelerated the degradation of p62.
Increased the expression of p-ASK1 and p-JNK, and decreased the expression of p-ERK.

Western Blot Analysis

Cell Line: HK-2 cells
Concentration: 20 nM
Incubation Time: 48 h
Result: Inhibited the protein expression of ECM proteins such as FN, Col-1, Col-3, and CTGF.
Specifically inhibited MMP13 rather than MMP10.
Inhibited Col-1, α-SMA, and CTGF.

RT-PCR

Cell Line: HK-2 cells
Concentration: 5, 10, 15, 20, 25, 30 nM
Incubation Time: 48 h
Result: Decreased the expression of type I collagen in a concentration-dependent manner.
Inhibited the gene expression of ECM proteins such as FN, Col-1, Col-3, and CTGF.
Significantly inhibited the mRNA expression of MMP10 (not obvious) and MMP13.

RT-PCR

Cell Line: SW1353 cells
Concentration: 10, 30, 50 ng/mL
Incubation Time: Pretreated at 1 h before IL-1β stimulation (24 h) for 25 h
Result: Decreased the mRNA expression of OA-related molecules (MMP13, TNF-α, IL-1β, COX1/2).

Western Blot Analysis

Cell Line: SW1353 cells
Concentration: 10, 30, 50 ng/mL
Incubation Time: Pretreated at 1 h before IL-1β stimulation (24 h) for 25 h
Result: Decreased the protein expression of OA-related molecules (MMP13, Collagen type II, TNF-α, IL-1β, and COX-2).
体内研究
(In Vivo)

Ecliptasaponin A (1-18 g/kg, p.o., 单次给药) 分布于多种组织中,浓度顺序为:肝脏 > 脾脏 > 肺 > 肾脏 > 心脏。
Ecliptasaponin A (80 mg/kg, p.o., 每日一次共 28 天) 通过抑制 TGF-β1 的表达预防小鼠纤维化。
Ecliptasaponin A (0.5-2.5 mg/kg, 左心室心肌心肌内单次注射) 在小鼠急性心肌梗死 (AMI) 模型中具有心脏保护作用。
Ecliptasaponin A (25-50 mg/kg, i.p., 共 21 天) 在肺癌裸鼠中可显著抑制肿瘤生长。
Ecliptasaponin A (80 mg/kg, p.o., 每日一次共 10 天) 减少肾纤维化单侧输尿管梗阻 (UUO) 小鼠的肾胶原纤维沉积和肾细胞外基质 (ECM) 蛋白的表达。
Ecliptasaponin A (200 mg/mL, 和 Specnuezhenide (MS-V03969) 连用, p.o., 每日一次共 30 天) 在早发性卵巢功能不全 (POF) 小鼠中改善基础特征和性激素水平。

Animal Model: Pulmonary fibrosis model induced by Bleomycin (MS-R86735) established in adult male ICR mice (6-7 weeks)
Dosage: 80 mg/kg
Administration: Oral administration (p.o.), once daily for 28 days
Result: Blocked BLM-induced histological changes of lung tissue.
Decreased the high levels of TGF-β1 and α-SMA.
Animal Model: AMI model induced by underwent left anterior descending coronary artery (LAD) ligation established in male SPF C57/BL6 mice, aged 8-10 weeks and weighing 23-25 g
Dosage: 0.5, 1.25, and 2.5 mg/kg
Administration: Intramyocardial injection of the left ventricular myocardium, single dose
Result: Significantly improved ejection fraction (EF%) and short-axis shortening rate (FS%).
Significantly reduced the area of myocardial infarction.
Reduced myocardial cell apoptosis and inflammatory cell infiltration.
Significantly reduced the expressions of HMGB1 and TLR4, as well as the phosphorylation of p-IkBα and p-P65, and the levels of inflammatory factors IL-1β, IL-6, and TNF-α.
Significantly enriched HMGB1/TLR4/NF-κB pathway.
Animal Model: H460 cells induced xenograft tumor model established in male BALB-c nude mice (4-week-old)
Dosage: 25 and 50 mg/kg
Administration: Intraperitoneal injection (i.p.), for 21 days
Result: Decreased the tumor weight and volume.
No significant biological toxicity.
Animal Model: Renal fibrosis UUO model established in six-week-old C57BL/6 J mice
Dosage: 80 mg/kg
Administration: Oral administration (p.o.), once daily for 10 days
Result: Ameliorated the obstructive kidney weight ratio.
Attenuated histological damage and collagen deposition in the kidneys.
Animal Model: POF model established in SPF-grade female C57 mice, 6-8 weeks
Dosage: 200 mg/mL with Specnuezhenide
Administration: Oral administration (p.o.), once daily for 30 days
Result: Increased the ovarian index and serum estradiol (E2) levels.
Reduced the level of follicle-stimulating hormone (FSH).
Extended the emotional cycle.
Increased the number and diameter of follicles.
Promoted ovarian angiogenesis (increase the expression of CD31 and VEGFA).
性状 固体
颜色 White to off-white

化学信息

分子量 634.84
分子式 C36H58O9
CAS No. 78285-90-2
别名 旱莲苷A

储存&溶解度

体内实验配方
10% DMSO+90% Saline: < 10 mg/mL (15.75 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 10 mg/mL (15.75 mM), Solution.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (157.52 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM1.5752 mL7.8760 mL15.7520 mL39.3800 mL
5 mM0.3150 mL1.5752 mL3.1504 mL7.8760 mL
10 mM0.1575 mL0.7876 mL1.5752 mL3.9380 mL
15 mM0.1050 mL0.5251 mL1.0501 mL2.6253 mL
20 mM0.0788 mL0.3938 mL0.7876 mL1.9690 mL
25 mM0.0630 mL0.3150 mL0.6301 mL1.5752 mL
30 mM0.0525 mL0.2625 mL0.5251 mL1.3127 mL
40 mM0.0394 mL0.1969 mL0.3938 mL0.9845 mL
50 mM0.0315 mL0.1575 mL0.3150 mL0.7876 mL
60 mM0.0263 mL0.1313 mL0.2625 mL0.6563 mL
80 mM0.0197 mL0.0984 mL0.1969 mL0.4922 mL
100 mM0.0158 mL0.0788 mL0.1575 mL0.3938 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

早莲苷 A 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础